Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

Who May Qualify: - • Ability to understand and the willingness to sign a written willing to sign a consent form document. - Age ≥ 18 years and ≤ 80 years. - Eastern Cooperative Oncology Group (ECOG) performance status 0-2. - diagnosed by tissue sample (biopsy-confirmed) metastatic pancreas adenocarcinoma. - Tumor progression after two lines of treatments. - Adequate organ performance based on laboratory blood tests. - Presence of at least of one measurable lesion in agreement to RECIST criteria. - The expected survival ≥ 1 months. - Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Who Should NOT Join This Trial: - • The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas. - Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc. - Pregnant or nursing women. - Glucose-6-phosphate dehydrogenase (G6PD) deficiency. - Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results. - Renal insufficiency or dialysis - Other serious accompanying illnesses, which, in the researcher\'s opinion, could seriously adversely affect the safety of the treatment. - Patients who are unwilling or unable to comply with study procedures. Always talk to your doctor about whether this trial is right for you.